1834 Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

1834 Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-435	Closed	-$310K	–	219
2024 Q4	$310K	Sell	435 -9	-2%	-$7.55K	0.04%	191
2024 Q3	$467K	Hold	444	–	–	0.05%	169
2024 Q2	$467K	Hold	444	–	–	0.06%	171
2024 Q1	$427K	Sell	444 -55	-11%	-$52.3K	0.05%	174
2023 Q4	$438K	Sell	499 -1,235	-71%	-$1.02M	0.05%	178
2023 Q3	$1.43M	Sell	1,734 -17	-1%	-$13.4K	0.18%	104
2023 Q2	$1.26M	Sell	1,751 -197	-10%	-$152K	0.15%	109
2023 Q1	$1.6M	Buy	+1,948	New	+$1.47M	0.19%	101

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1834 Investment Advisors's REGN Position: Q1 2025 in Review

1834 Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 435 shares — an estimated $310K sold.

1834 Investment Advisors first reported a position in REGN in Q1 2023 and held it in 8 quarters. The position peaked at $1.6M in Q1 2023. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

1834 Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
1834 Investment Advisors sold 435 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $310K.
1834 Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 8 quarters.
1834 Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.6M in Q1 2023.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on 1834 Investment Advisors's 13F filing for Q1 2025, filed 9 May 2025.